Unilabs Partners with SOPHiA GENETICS to Utilize AI Technology for HRD Detection

Unilabs, a prominent diagnostic provider in Europe, has recently implemented the SOPHiA DDM™ Platform across its network in Switzerland to enhance cancer diagnostics and treatment. This cutting-edge technology will enable Unilabs to test for HRD-status in solid tumors and provide expedited analysis to patients.

Founded in Switzerland in 1987, Unilabs conducts over 221 million tests annually and is known for its innovative diagnostic services. By incorporating the SOPHiA DDM™ Platform, Unilabs aims to offer faster and more accurate diagnostics to its customers, ultimately advancing the use of precision medicine.

HRD, a condition where a cell’s ability to repair DNA is impaired, is a prevalent alteration in ovarian cancer. Detecting HRD is crucial for determining the most effective treatment options. The SOPHiA DDM™ Platform utilizes AI and machine learning to analyze complex data sets from next-generation sequencing, providing reliable HRD results quickly and efficiently.

Mattia Schmid, Scientific Manager at Unilabs, expressed excitement about the partnership with SOPHiA GENETICS, stating that the technology will help deliver the best outcomes for patients. Kevin Puylaert, Managing Director at SOPHiA GENETICS, emphasized the importance of identifying HRD-status in facilitating precision medicine for ovarian cancer patients worldwide.

The collaboration between Unilabs and SOPHiA GENETICS signifies a significant step towards advancing cancer diagnostics and treatment in Switzerland and beyond. With the implementation of the SOPHiA DDM™ Platform, Unilabs is poised to continue offering top-notch testing and diagnostics to patients across Europe.